DALLAS, July 29, 2015 /PRNewswire/ --
RnRMarketResearch.com adds Escherichia Coli Infections - Pipeline Review, H1 2015 on therapeutic development as well as E Coli Infections Global Clinical Trials Review, H1, 2015 market research reports to the pharmaceuticals category of its library.
Complete report on Escherichia coli infections therapeutic pipeline spread across 156 pages, talking about 35 companies, important drug profiles and supported with 58 tables and 15 figures is now available at http://www.rnrmarketresearch.com/escherichia-coli-infections-pipeline-review-h1-2015-market-report.html .
The Escherichia Coli Infections therapeutics pipeline review report provides assessment information on assessment by monotherapy products, by combination products, by target, by mechanism of action, by route of administration and by molecule type. E. coli infections drug profiles covered in this research include A-3APO, AA-139, ACE-920, Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections, BNT-006, BXN-112, Debio-1454, Drug for Infectious Diseases, Drugs for Bacterial Infections, dusquetide, EcoXyn-4V, enterotoxigenic escherichia coli vaccine, enterotoxigenic escherichia coli vaccine, Escherichia coli (whole cell) vaccine, Escherichia coli vaccine, ETEC Adhesin-Based Vaccine, ETEC Vaccine, EV-035, extraintestinal pathogenic escherichia coli vaccine, GN snare, GN-4474, IMM-363, INX-201, MBX-2319, MDN-0057, Monoclonal Antibodies for Escherichia Coli Infections, NAB-7061NAB-739, NAB-741, NOSO-95300, NP-432, NVC-727, NXC-4720, PMX-1278, PMX-1363, PMX-1405, PMX-247,
PP-0121, pritoxaximab + setoxaximab , Proteins for Infectious Diseases, PT-4, Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections, RX-05, RXP-873, SB-041, Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections, Shigetec, SLP-0901, SLP-0905, Small Molecule for Gram-Negative Nosocomial Infections, Small Molecule to Inhibit Rns and VirF for Bacterial Infections,
Small Molecules for Bacterial Infections, Small Molecules for Escherichia Coli Infections,Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections, Small Molecules to Inhibit 23S Ribosomal RNA for Infections, Small Molecules to Inhibit 30S RNA, Topoisomerases II and IV for Bacterial Infections, Small Molecules to Inhibit RecA for Bacterial Infections, Synthetic Peptide for Oncology and Infectious Disease, Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease and Synthetic Peptides for Escherichia Coli Infections.
Companies involved in escherichia coli infections therapeutics development and mentioned in this research include Adenium Biotech ApS, Arsanis Biosciences GmbH, AvidBiotics Corp., Bellus Health Inc.,
Bioorganic Research and Services S.A., Cellceutix Corporation, Chiesi Farmaceutici SpA, ConjuGon, Inc.,
Debiopharm International S.A., Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., GangaGen Inc.,
Genentech, Inc., GlaxoSmithKline Plc, Immuron Limited, Melinta Therapeutics, Inc , Microbiotix, Inc., Mucosis B.V., Nabriva Therapeutics AG, Navigen Pharmaceuticals, Inc., Northern Antibiotics Oy, Nosopharm SAS, NovaBay Pharmaceuticals, Inc., Novabiotics Limited, Nymox Pharmaceutical Corporation, Pherecydes Pharma SA, Phico Therapeutics Limited, Procarta Biosystems Ltd, Sanofi Pasteur SA, Sealife PHARMA GMBH, Sequoia Sciences, Inc., Soligenix, Inc., Spider Biotech, Syntiron LLC and Trana Discovery, Inc. Order a copy of Escherichia Coli Infections - Pipeline Review, H1 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=397263 .
This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. NOTE: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The second research titled Escherichia Coli Infections Global Clinical Trials Review, H1, 2015 provides top line data relating to the clinical trials on Escherichia Coli Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). These clinical trial reports are generated using a proprietary database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
This E.coli infections clinical trials review report assists in formulating key business strategies with regards to investment as well as helps in identifying prominent locations for conducting clinical trials which saves time and cost. It provides top level analysis of global clinical trials market which helps in identifying key business opportunities and supports understanding of trials count and enrollment trends by country in global therapeutics market. The research also aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials while facilitating clinical trial assessment of the indication on a global, regional and country level.
Clinical trial overview of top companies include Teijin Limited, NIZO food research, Bellus Health Inc., Thallion Pharmaceuticals Inc. (Inactive), Pfizer Inc., GlaxoSmithKline Plc, Cubist Pharmaceuticals, Inc., Berna Biotech Ltd, Arla Foods amba and Alexion Pharmaceuticals, Inc. are covered in this research available at http://www.rnrmarketresearch.com/escherichia-coli-infections-global-clinical-trials-review-h1-2015-market-report.html. Additionally, E.coli infections clinical trial overview of top institutes and government organizations like The National Institute of Allergy and Infectious Diseases, Assistance Publique - Hopitaux de Paris, Medical University of Vienna, The Hong Kong Polytechnic University and Uppsala University is also provided.
The report provides a snapshot of the global E coli infections clinical trials landscape and top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status. It reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company and offers all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment. The research provides information on enrollment trends for the past five years as well as latest news for the past three months. Order a copy of Escherichia Coli Infections Global Clinical Trials Review, H1, 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=395681 .
Explore more reports on clinical trials, therapeutics and overall pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed
